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Aim: To find new genetic loci associated with statin response, and to investigate the 
association of a genetic risk score (GRS) with this outcome. Patients & methods: In a 
discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of 
approximately 50000 single nucleotide polymorphisms on statin response, following 
up associations with p < 1 × 10-4 (three independent studies, 5314 individuals). We 
further assessed the effect of a GRS based on SNPs in ABCG2, LPA and APOE. Results: 
No new SNPs were found associated with statin response. The GRS was associated 
with reduced statin response: 0.0394 mmol/l per allele (95% CI: 0.0171–0.0617, 
p = 5.37 × 10-4). Conclusion: The GRS was associated with statin response, but the 
small effect size (∼2% of the average low-density lipoprotein cholesterol reduction) 
limits applicability. 
First draft submitted: 27 March 2015; Accepted for publication: 27 January 2016; 
Published online: 5 April 2016
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The primary goal of statin therapy is to 
reduce plasma low-density lipoprotein cho-
lesterol (LDLc) levels, thereby lowering the 
risk of cardiovascular events. Statin treat-
ment has proven effective in reducing risk for 
major coronary events and all-cause mortal-
ity (average risk reductions of 27 and 15%, 
respectively) [1,2]. However, the response 
to statin therapy shows a degree of inter-
individual variability influenced by genetic 
variation and environmental factors [3,4].
A better understanding of the bio logical 
pathways and determinants involved in this 
variation in statin response could lead to 
improved treatment. Genome-wide associa-
tion studies (GWAS) have identified many 
(95+) loci associated with plasma lipid and 
lipoprotein traits, including several not pre-
viously known to be related to lipoprotein 
metabolism [5]. In contrast, studies search-
ing for SNPs related to statin response have 
yielded a relatively low number of robust 
results. Evidence from several studies shows 
that the ε4 allele of APOE is associated with 
decreased LDLc lowering by statin ther-
apy [3,6–9]. Additionally, SNPs at ABCG2 and 
LPA were associated with LDLc response at 
the level of genome-wide significance [8,9]. 
These GWAS have generally been performed 
in data from randomized controlled trials 
(RCTs), and it is not certain if these results 
also apply to statin users in the general popu-
lation. In addition, other approaches than 
hypothesis-free GWAS genotyping across 
the genome may be a useful complement to 
uncover further associated genetic variants.
Using a gene-centric approach, we therefore 
aimed to identify additional genetic associa-
tions underlying interindividual variation in 
statin response. To this end, we performed a 
meta-analysis of five studies comprising 2159 
individuals of European ancestry by using 
the candidate-gene ITMAT-Broad-CARe 
(IBC) array, also known as the  CardioChip 
or the Human CVD BeadArray [10]. This 
array aims to capture genetic diversity related 
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to cardiovascular, inflammatory and metabolic phe-
notypes in greater depth than classic hypothesis-free 
GWAS using approximately 50000 SNPs selected 
across approximately 2000 candidate loci. Compared 
to normal GWAS arrays, the equal or greater marker 
density might permit a better identification of multiple 
functional polymorphisms, or their proxies, at each 
locus.
Compared with single SNPs, genetic risk scores 
consisting of multiple SNPs previously identified by 
GWAS increase statistical power to find associations, 
and summarize the total genetic effect; therefore these 
risk scores might be of more clinical value than single 
SNPs. However, as the single SNPs robustly associated 
with statin response were found in GWA studies with 
RCT participants, the value of a genetic risk score in 
the general population is at present unclear. We there-
fore investigated whether a genetic risk score is asso-
ciated with statin response in the lowering of LDLc 
response in observational studies as well as in RCTs.
Methods
Study selection
In our focus on a gene-centric discovery approach, we 
selected studies that used the 50k Cardiochip array [10] 
for genotyping, having more than one measurement of 
LDLc, information on statin use and participants of 
European ancestry. We included five studies, the ARIC 
study, FHS, MESA, WHII and AMC-PAS. All these 
studies were observational. Replication of the results 
was sought in other studies, as detailed below. The 
baseline measurement was defined in these studies as 
the last measurement of LDLc before reporting use of 
statins. The baseline value is therefore not necessarily 
measured on the same visit for all participants. The on-
statin measurement was defined as the first measure-
ment of LDLc after the first report of statin use. We 
then calculated LDLc change (δ LDLc) by subtracting 
the baseline value from the on-statin value. Details of 
the set-up and analysis for each study can be found 
in the Supplementary Material. Informed consent for 
DNA analysis was received from each respective local 
institutional and/or national ethical review board.
Genotyping & quality control
Genotyping was performed using the gene-centric IBC 
array [10]. Several studies have been published using 
this array and have confirmed previously established 
associations and identified new associations of SNPs 
with several phenotypes and disease outcomes, includ-
ing blood pressure [11], coronary artery disease [12,13], 
plasma lipids [14] and Type 2 diabetes (T2D) [15]. Array 
data were clustered into genotypes with Illumina 
 BeadStudio software (Illumina, CA, USA). Qual-
ity-control filters were applied within each cohort at 
the sample and SNP levels and are described in the 
Supplementary Methods. SNPs with a call rate below 
95% or Hardy–Weinberg p-value <1 × 10-06 were 
excluded from analysis. Only SNPs with a minor allele 
 frequency >1% were included in this analysis.
Association analysis
We used linear regression to test the association of a 
SNP with LDLc change. Association testing was per-
formed using an additive genetic model, adjusting 
for age, sex, baseline LDLc and other relevant study 
covariates (see Supplementary Material). Samples were 
excluded based on ancestry outliers by PCA, removals 
of duplicates and first and second degree relatives. Each 
study was further adjusted for population stratification 
using the principal component approach in EIGEN-
STRAT [16]. Adjustment for baseline LDLc was neces-
sary because many of the SNPs previously associated 
with statin response are also associated with cholesterol 
levels before treatment with statins. Meta-analysis was 
performed with METAL [17], using the inverse vari-
ance method and a fixed-effects model and I² as a mea-
sure of between-study heterogeneity [18]. To maintain 
the conventional 5% false-positive rate, the appropriate 
multiple-testing-corrected threshold for statistical sig-
nificance was set at p < 2.4 × 10-6, taking into account 
the approximately 20,500 independent tests generated 
for individuals of European descent [19]. We selected all 
SNPs reaching p < 1 × 10-4 for subsequent replication. 
Power calculations for the chip-wide association analy-
sis were done using QUANTO [20], assuming a mean 
LDLc-reduction of 1.3 mmol/l with a SD of 0.6, and a 
minor allele frequency of 20%.
Replication
Independent replication was attempted for associa-
tions with p < 1 × 10-4. Look-ups were performed in 
three additional studies, the UK and Irish subjects 
from the observational and the randomized arm of the 
ASCOT-UK RCT, ASCOT-UK OBS and the RCT 
JUPITER, with data from a total of 5314 individu-
als in the three studies. Details of characteristics and 
methodological details for cohorts can be found in the 
Supplementary Material. The association of the genetic 
risk score was also investigated in these replication 
studies.
Risk score composition
We calculated a genetic risk score (genetic risk score) 
on the basis of previous findings related to statin 
response, selecting risk alleles achieving genome-
wide significance (p < 5 × 10-8) in GWAS of LDLc 
change, replicated in at least one other study. In total, 
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we selected three SNPs reported by Chasman et al. [9], 
independently found by Deshmukh et al. [8] and 
Tomlinson et al. [21]. These SNPs were rs2231142 (a 
proxy SNP with r2 = 0.92 for rs2199936 in ABCG2), 
rs10455872 in LPA and rs2075650 (a proxy SNP with 
r2 = 0.95 for rs71352238 in APOE). For all three loci, 
the lead SNP or a good proxy SNP (r2 > 0.8) was avail-
able. One of the studies, AMC-PAS, was not included 
in this analysis due to the unavailability of one of the 
SNPs in the risk score.
The approach used to calculate the genetic risk 
score was a simple count of the alleles decreasing statin 
response, in other words, lowering the efficacy and 
bringing the response closer to zero. The simple count 
approach, rather than weighted scores, was chosen as 
SNP effects found in GWAS were similar.
Association of the risk score with delta LDLc was 
investigated using linear regression, using the risk 
score as a continuous variable. Models were adjusted 
for age, sex, baseline LDLc and relevant study covari-
ates (e.g., correction for population  stratification 
with  principal components) as specified in the 
 Supplementary Materials.
Study-specific estimates of the risk score effect (β) 
were subsequently combined using random effects 
meta-analysis with the inverse variance weighting 
method, using R [22] version 3.0.2 and the ‘meta’ pack-
age [23] 3.5–0. A p-value < 0.05 was considered to con-
stitute a statistically significant effect. We used I² to 
quantify between-study heterogeneity [18].
Results
Characteristics of studies
For the discovery dataset, we included five studies 
with a total of 1991 participants (Table 1). This gave us 
80% statistical power to detect effects of 0.125 mmol/l 
per allele, which is close to the effect sizes found by 
other studies [9]. LDLc levels were consistently lower 
on statin use compared with before statin use, with 
an average reduction of 1.18 mmol/l. In the replica-
tion phase, a total of 5314 participants in three stud-
ies were included with an average LDLc reduction of 
1.25 mmol/l. For the risk score analysis, one study was 
excluded due to unavailable SNPs, and the total sample 
size was 7121.
Association analysis
A total of 37,465 SNPs in five cohort stud-
ies were tested in the association analysis. No 
SNPs reached the significance threshold of 
p < 2.4 × 10-6 (Supplementary Figure 1: QQ-plot, 
Supplementary Figure 2: Manhattan plot). One SNP 
reached p < 1 × 10-4 (Table 2), rs17171676 on chromo-
some 7, and was taken to the replication phase. This T
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SNP was not statistically significantly associated in 
this replication phase (replication p > 0.05), nor in a 
joint analysis of the discovery and replication phase 
(Table 2).
Association of genetic risk score
The distribution of the risk score (Table 3) shows 
that only 4% of the individuals of European ances-
try have four or more risk alleles, with the majority 
(more than 95%) having one to three alleles. Although 
statins show a consistent average reduction in LDLc, 
a higher genetic risk score is associated with a smaller 
change in LDLc due to statin treatment. The risk 
score decreased the effect of statins on δ LDLc by 
0.0394 mmol/l per allele (95% CI: 0.0171; 0.0617), 
with a p-value of 5.37 × 10-4 (Figure 1). Heterogeneity 
was low in this analysis (I2 = 18%). When adjustment 
for baseline LDLc was not included, the effect size 
was similar, 0.0354 mmol/l per allele but with a larger 
95% CI (0.0054; 0.0654), which is still statistically 
significant (p = 0. 00206). The effect size was larger 
in the observational studies (β = 0.0509 mmol/l per 
allele, 95% CI: 0.0172; 0.0847, p = 0.0031) than in the 
RCTs (β = 0.0391 mmol/l per allele, 95% CI: -0.0097; 
0.0880, p = 0.117).
Discussion
Using data from six population-based cohort stud-
ies and two RCTs, with a total of 7305 participants, 
we investigated the effect of common genetic varia-
tion on the LDLc response to statins using a cardio-
vascular gene-centric SNP array. The LDLc lowering 
effect of statins we found in the whole population, 
-1.30 mmol/l, is in the range of the values reported in 
a large meta-analyses of clinical trials (from -1.08 to 
-1.8 mmol/l) [1,24].
No new loci were found to be associated to LDLc 
response to statins. Although one locus reached a 
p-value of p < 1 × 10-4, it could be replicated. These 
results are consistent with a genetic model involving 
multiple genes, each with modest effects, on LDLc 
change. The observation that GWAS have revealed 
robust associations with statin-induced response sug-
gests that there are genuine genetic factors, but that 
much larger samples will be needed to find them with 
unequivocal evidence.
We also investigated the association of a genetic risk 
score, consisting of SNPs previously associated with 
statin response at the genome-wide level, with statin-
induced LDLc lowering. The direction of effect of 
the risk score agreed with what was previously found. 
However, the effect was small, 0.0313 mmol/l per 
extra allele, which is about 2% of the total lowering of 
LDLc we found in the studies included in our  analysis. T
ab
le
 2
. S
N
P 
as
so
ci
at
ed
 w
it
h
 s
ta
ti
n
 r
es
p
o
n
se
 in
 t
h
e 
ch
ip
-w
id
e 
an
al
ys
is
 a
t 
p
 <
 1
 ×
 1
0
-4
.
SN
P
C
H
R
Po
si
ti
o
n
G
en
e
D
is
co
ve
ry
R
ep
lic
at
io
n
O
ve
ra
ll
Ef
fe
ct
 (
95
%
 C
I)
p
-v
al
u
e
Ef
fe
ct
 (
95
%
 C
I)
p
-v
al
u
e
Ef
fe
ct
 (
95
%
 C
I)
p
-v
al
u
e 
rs
17
17
16
76
7
4
03
07
15
4
C
7o
rf
10
-0
.2
99
 (
-0
.4
50
4
; -
0.
14
92
)
9.
57
 ×
 1
0
-5
0.
03
15
 (
-0
.0
29
2
; 0
.0
92
2
)
0.
31
67
-0
.0
16
0 
(-
0.
07
30
; 0
.0
41
0
)
0.
58
2
Ef
fe
ct
 is
 in
 m
m
ol
/l.
C
H
R:
 C
hr
om
os
om
e;
 B
P:
 B
as
e 
pa
ir,
 b
as
ed
 o
n 
G
RC
h3
6.
 
www.futuremedicine.com 587
Figure 1. Forest plot for the association between the genetic risk score and low-density lipoprotein cholesterol 
reduction. Analyses were adjusted for baseline LDLc values.  
LDLc: Low-density lipoprotein cholesterol.
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Further more, more than 95% of individuals with Euro-
pean ancestry only have 1–3 risk alleles, resulting in a 
maximum of 0.09 mmol/l difference in statin response. 
The small effect of the risk score, the modest effective 
range of a risk score based on three SNPs, and the fact 
that LDLc was substantially reduced in most partici-
pants starting statin therapy, suggest that the possible 
role of genetics in the prediction of statin efficacy is 
small. The same conclusion was also reached by inves-
tigators studying the effects of single SNPs [8,9,25]. This 
study adds to the existing knowledge that taking the 
genetic background of a patient into account when pre-
scribing statins, based on the known SNPs that affect 
statin-efficacy, does not seem justified. Although larger 
sample sizes in future studies may well result in the 
identification of additional loci that influence LDLc 
response, it seems unlikely that a revised genetic risk 
score would explain a sufficiently large fraction of the 
observed interindividual variation in LDLc response 
for it to be clinically useful. These limitations not-
withstanding, genetic research into adverse events such 
as myopathy [26], and rhabdomyolysis might be used 
to predict and prevent these side effects, as has been 
done for other drugs and side effects, as effect sizes for 
adverse drug reactions may be much larger [27,28].
It is important to distinguish between direct genetic 
effects on (baseline) LDLc and genetic effects on statin-
induced LDLc reduction. These can be difficult to sepa-
rate when there are also associations with baseline LDLc, 
as is the case for the SNPs used in the risk score [5,9]. 
Adjusting for baseline LDLc values slightly increased 
the effect of the risk score, and narrowed the 95% CI. 
This indicates that associations with LDLc change can 
be obscured by effects of SNPs on baseline LDLc, and 
underscores the importance of this  adjustment.
A strong point of this study is that it includes evi-
dence from both observational cohort studies and clini-
cal trials, demonstrating that the genetic risk score has 
a similar effect in both types of studies. A limitation of 
this study, however, is that we were not able to investi-
gate the genetic effects for the different types of statins 
separately. This is partly a result of lack of data: the 
studies in the discovery phase have incomplete dosing 
and statin type data or complete absence of it. This is 
different from the data of clinical trials ASCOT and 
JUPITER (10 mg/day atorvastatin and 20 mg/dat 
rosuvastatin, respectively). However, when we would 
restrict our analyses to those subjects with information 
on dose and type of statin, the power reduction due 
to a lower participant count would negatively impact 
the possible identification of SNPs affecting statin 
effectiveness. Further, the study is small compared 
with meta- analyses of main SNP effects, which now 
typically include more than 100,000 participants [5]. 
This is a result of the fact that only a subset of the par-
ticipants in observational studies (and also of placebo-
controlled statin trials) is prescribed statin medica-
tion. Additionally, several population-based studies 
only have cholesterol measures at only one time point, 
excluding the possibility of investigating longitudinal 
changes in LDLc, while other studies do not have (reli-
able) information on drug use. For pharmacogenetic 
Table 3. Distribution of genetic risk score in samples of ARIC study, MESA and FHS.
0 alleles 1 alleles 2 alleles 3 alleles 4 alleles 5 alleles 6 alleles
0.66% 13.07% 58.10% 24.11% 3.84% 0.22% 0.01%
Risk alleles were defined as alleles associated with smaller LDLc reduction in the genes ABCG2, LPA and APOE.
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research, which is hampered by relatively small sam-
ple sizes [29], it would be valuable if drug use data and 
longi tudinal follow-up data were routinely collected in 
large samples.
Conclusion 
In summary, we investigated whether new individ-
ual SNPs associated with statin-induced change in 
LDLc levels could be identified from a gene-centric 
discovery approach; we further investigated whether 
a genetic risk score, composed of SNPs previously 
associated with statin response, was associated with 
statin-induced change in LDLc levels. We did not 
find new SNPs associated with the magnitude of 
statin-induced LDLc reduction, but we found that 
there is a small but statistically significant association 
of the risk score with statin-induced LDLc reduction. 
However, use of statins lowers LDLc substantially 
regardless of genotype, and each additional allele 
in the genetic risk score decreases the total LDLc 
change only by 2%. Therefore, genotype-based clini-
cal decision making for statin therapy is unlikely to 
improve efficacy, and at this moment there is no role 
for genetic testing in clinical practice to guide statin 
treatment.
Future perspective
To date, several polymorphisms have been found to 
affect response to statin therapy based on the achieved 
lowering of LDLc. A further increase in the num-
ber of loci associated with LDLc response can prob-
ably be achieved with larger studies using GWAS 
methodology, although large numbers of statin users 
are required to effectively perform these. Because of 
the small effect sizes identified, there does not seem 
to be a genetically identifiable subgroup in which 
statins do not lower LDLc. The utility of genetic 
research into statin response might lie more in a bet-
ter  understanding of pharmacokinetics and pharma-
codynamics, and  ultimately the development of new 
drugs, than in direct clinical application (e.g., choos-
ing a drug type or dose). Alternatively, research into 
the (prediction of) adverse drug reactions side effects 
of statin therapy might have a faster impact on clinical 
decisions.
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Executive summary
Background
•	 The response to statin therapy shows a degree of interindividual variability influenced by genetic variation 
and environmental factors.
•	 Several studies have found genetic variants that have an effect on the statin-induced low-density lipoprotein 
cholesterol (LDLc) lowering.
Patients & methods
•	 We investigated the association of statin response on a cardiovascular gene-centric SNP array in a discovery 
dataset consisting of five studies and 1991 individuals, aiming to find novel associations with this outcome.
•	 We further assessed the effect of a composite genetic risk score on statin response, based on previously 
associated SNPs in ABCG2, LPA and APOE.
Results: main findings
•	 A genetic risk score was significantly associated with LDLc-response to statins. We found no novel SNPs to be 
significantly associated with LDLc-response to statins
•	 The small effect size of this association suggests that the applicability of this score in predicting statin 
response in clinical practice will be limited.
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